These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 16782798)
1. A high-throughput migration assay reveals HER2-mediated cell migration arising from increased directional persistence. Kumar N; Zaman MH; Kim HD; Lauffenburger DA Biophys J; 2006 Aug; 91(4):L32-4. PubMed ID: 16782798 [TBL] [Abstract][Full Text] [Related]
2. Modeling HER2 effects on cell behavior from mass spectrometry phosphotyrosine data. Kumar N; Wolf-Yadlin A; White FM; Lauffenburger DA PLoS Comput Biol; 2007 Jan; 3(1):e4. PubMed ID: 17206861 [TBL] [Abstract][Full Text] [Related]
3. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination. Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199 [TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function. Wang SE; Wu FY; Shin I; Qu S; Arteaga CL Mol Cell Biol; 2005 Jun; 25(11):4703-15. PubMed ID: 15899872 [TBL] [Abstract][Full Text] [Related]
5. Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects. Hendriks BS; Opresko LK; Wiley HS; Lauffenburger D Cancer Res; 2003 Mar; 63(5):1130-7. PubMed ID: 12615732 [TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Gilbertson RJ; Perry RH; Kelly PJ; Pearson AD; Lunec J Cancer Res; 1997 Aug; 57(15):3272-80. PubMed ID: 9242460 [TBL] [Abstract][Full Text] [Related]
9. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817 [TBL] [Abstract][Full Text] [Related]
10. Human EGF receptor (HER) family and heregulin members are differentially expressed in epidermal keratinocytes and modulate differentiation. De Potter IY; Poumay Y; Squillace KA; Pittelkow MR Exp Cell Res; 2001 Dec; 271(2):315-28. PubMed ID: 11716544 [TBL] [Abstract][Full Text] [Related]
11. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates. Razumienko EJ; Scollard DA; Reilly RM J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164 [TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2. Ram TG; Dilts CA; Dziubinski ML; Pierce LJ; Ethier SP Mol Carcinog; 1996 Mar; 15(3):227-38. PubMed ID: 8597535 [TBL] [Abstract][Full Text] [Related]
13. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304 [TBL] [Abstract][Full Text] [Related]
14. Single-molecule study of lateral mobility of epidermal growth factor receptor 2/HER2 on activation. Xiao Z; Ma X; Jiang Y; Zhao Z; Lai B; Liao J; Yue J; Fang X J Phys Chem B; 2008 Apr; 112(13):4140-5. PubMed ID: 18324805 [TBL] [Abstract][Full Text] [Related]
15. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Sartor CI; Zhou H; Kozlowska E; Guttridge K; Kawata E; Caskey L; Harrelson J; Hynes N; Ethier S; Calvo B; Earp HS Mol Cell Biol; 2001 Jul; 21(13):4265-75. PubMed ID: 11390655 [TBL] [Abstract][Full Text] [Related]
16. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Vadlamudi R; Mandal M; Adam L; Steinbach G; Mendelsohn J; Kumar R Oncogene; 1999 Jan; 18(2):305-14. PubMed ID: 9927187 [TBL] [Abstract][Full Text] [Related]
17. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation. Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474 [TBL] [Abstract][Full Text] [Related]
18. Study of inhibition effect of herceptin on interaction between heregulin and erbB receptors HER3/HER2 by single-molecule force spectroscopy. Shi X; Xu L; Yu J; Fang X Exp Cell Res; 2009 Oct; 315(16):2847-55. PubMed ID: 19497323 [TBL] [Abstract][Full Text] [Related]
19. Blockade of a key region in the extracellular domain inhibits HER2 dimerization and signaling. Menendez JA; Schroeder B; Peirce SK; Vellon L; Papadimitropoulou A; Espinoza I; Lupu R J Natl Cancer Inst; 2015 Jun; 107(6):djv090. PubMed ID: 25888715 [TBL] [Abstract][Full Text] [Related]
20. The heregulin/human epidermal growth factor receptor as a new growth factor system in melanoma with multiple ways of deregulation. Stove C; Stove V; Derycke L; Van Marck V; Mareel M; Bracke M J Invest Dermatol; 2003 Oct; 121(4):802-12. PubMed ID: 14632199 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]